The Treatment Outcomes of Medullary Thyroid Carcinoma / 대한이비인후과학회지
Korean Journal of Otolaryngology - Head and Neck Surgery
;
: 166-172, 2012.
Article
in Korean
| WPRIM
| ID: wpr-647869
ABSTRACT
BACKGROUND AND OBJECTIVES:
The aim of this study was to evaluate the treatment outcomes of medullary thyroid carcinoma (MTC) by retrospective data analysis. SUBJECTS ANDMETHOD:
We conducted a retrospective chart review of 17 cases of pathologically proven MTC patients who were treated from 1998 to 2010 at the department of Otolaryngology-Head and Neck Surgery, Kosin University College of Medicine.RESULTS:
The mean tumor size was 2.32 cm (0.5-3.4 cm). Seventy-one percent of patients were diagnosed with advanced stage (III or IV) of MTC. We performed RET genetic screening in 8 of 17 patients. Hereditary MTC was found in 3 of 17 patients (18%) and sporadic MTC was found in 14 of 17 (82%). The preoperative assessment of basal serum calcitonin (CT) level was performed in 15 of 17 patents. Eleven patients had elevated basal calcitonin levels (>13 pg/mL). After the operation for MTC, the serum CT levels were elevated in 7 patients. Overall 5-year survival rate was 94%. Normalization of serum calcitonin level was accomplished more frequently in the absence of extra thyroidal invasion (p=0.034), multifocal tumor (p=0.02).CONCLUSION:
The initial treatment of MTC is total thyroidectomy with central compartment neck dissection with or without lateral neck dissection. To detect recurrence or metastasis, regular checking of serum calcitonin is necessary. A better knowledge of prognostic factors could improve the management of MTC patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Neck Dissection
/
Recurrence
/
Thyroid Gland
/
Thyroidectomy
/
Calcitonin
/
Thyroid Neoplasms
/
Genetic Testing
/
Survival Rate
/
Retrospective Studies
/
Neck
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Otolaryngology - Head and Neck Surgery
Year:
2012
Type:
Article
Similar
MEDLINE
...
LILACS
LIS